
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
To describe clinical outcomes of both Y-90 RS and EBRT as initial therapy for solitary HCC.
This video is sponsored by Boston Scientific.






